Cargando…
Prostate cancer-derived holoclones: a novel and effective model for evaluating cancer stemness
Prostate cancer accounts for approximately 13.5% of all newly diagnosed male cancer cases. Significant clinical burdens remain in terms of ineffective prognostication, with overtreatment of insignificant disease. Additionally, the pathobiology underlying disease heterogeneity remains poorly understo...
Autores principales: | Flynn, Louise, Barr, Martin P., Baird, Anne-Marie, Smyth, Paul, Casey, Orla M., Blackshields, Gordon, Greene, John, Pennington, Stephen R., Hams, Emily, Fallon, Padraic G., O’Leary, John, Sheils, Orla, Finn, Stephen P. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7347552/ https://www.ncbi.nlm.nih.gov/pubmed/32647229 http://dx.doi.org/10.1038/s41598-020-68187-9 |
Ejemplares similares
-
Pluripotency markers are differentially induced by MEK inhibition in thyroid and melanoma BRAFV600E cell lines
por: Dorris, Emma R., et al.
Publicado: (2016) -
Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide
por: Greene, John, et al.
Publicado: (2019) -
An integrated analysis of the SOX2 microRNA response program in human pluripotent and nullipotent stem cell lines
por: Vencken, Sebastian F, et al.
Publicado: (2014) -
MIR141 Expression Differentiates Hashimoto Thyroiditis from PTC and Benign Thyrocytes in Irish Archival Thyroid Tissues
por: Dorris, Emma R., et al.
Publicado: (2012) -
Identifying novel hypoxia-associated markers of chemoresistance in ovarian cancer
por: McEvoy, Lynda M., et al.
Publicado: (2015)